Gender Differences in Clinical Presentations of Cystic Fibrosis Patients in Azeri Turkish Population

Article information

Tuberc Respir Dis. 2016;79(4):267-273
Publication date (electronic) : 2016 October 05
doi :
1Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2Department of Medical Genetic, Faculty of Natural Sciences, Center of Excellence for Biodiversity, University of Tabriz, Tabriz, Iran.
3Department of Physiology, Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
4Department of Pathology, Liver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
5Department of Pediatrics, Tabriz Children's Hospital, Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Address for correspondence: Mandana Rafeey, M.D. Department of Pediatrics, Tabriz Children's Hospital, Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, Iran. Phone: 98-9141146982, Fax: 98-4133373741,
Received 2015 October 12; Revised 2015 December 22; Accepted 2016 June 05.



Cystic fibrosis (CF) is an autosomal recessive disorder with several clinical presentations. This study was undertaken in the Azeri Turkish population in Iran, to investigate gender differences in the age at onset and diagnosis, age of death, and duration of illness of CF.


The data of 331 CF patients from 2001 to 2015 was surveyed. Parameters including age, sex, ΔF508 mutation, age at onset, age at diagnosis, age of death and clinical presentations were evaluated for both sexes, using descriptive analysis. The association of gender with these variables was studied using logistic regression, chi-square test and Mann-Whitney U test by SPSS version 18. Odds ratio with a confidence interval of 95% and p≤0.05 was considered statistically significant.


The study included 191 males (57.7%) and 140 females (42.3%), all showing statistically significant difference (p<0.001). Age duration differed between genders. Male and female patients were further under 9 and 4 years, respectively. The occurrence of ΔF508 mutation was 0.51 times more in females than in males. Age, diagnosis and sex were closely associated: males were diagnosed at a significantly later age than females (p=0.05). While this compression performed based on clinical presentations, males with respiratory disease had a later median age at diagnosis than females at lifespan (p=0.001). The risk of infertility in males was approximately two times greater than in females (p=0.02).


These findings indicate gender differences in CF patients. Future studies are needed to establish other differences and evaluate the causes for the gender variations.


Cystic fibrosis (CF; OMIM 219700) is the most common lethal autosomal recessive disorder caused by mutations on the cystic trans-membrane conductance regulator (CFTR) gene. It is a multisystem disorder affecting the gastrointestinal, respiratory, hepatobiliary, reproductive systems, and sweat glands123. It is observed in 1 in 2,000–3,000 live births in Europe. The incidence of CF in Asians is rare and unknown; however, it is estimated to be 1 in 10,000 in the Middle East (such as Iran, Turkey, and Lebanon)4. Although numerous mutations in the CFTR gene are a primary cause on the clinical manifestations of CF, recent research has established that various gender, modifier genes, environmental factors, and socioeconomic factors can modify the development and severity of CF35678.

While gender differences are known to exist due to variations in pathogenesis, mortality, morbidity, and survival, the reasons for such differences between sexes are not fully understood7910. It has been hypothesized that the nutritional status11011, social and emotional conditions of patients and their families, physical functions1213, cultural subjects14, hormonal changes115, and cultural and ethnic differences14 explain in part this gender gap. For example, female patients have less eating than males; hide some symptoms such as coughing public, perform less physical activities, and state an overestimation of their own weight111416. Here, we have summarized the data, which indicates that there is a "CF gender gap" in clinical course.

The retrospective researches, despite some disadvantages, have an important role in depicting the disease1718. Innovation and non-repetition of these studies are determinate factors. This research has been conducted after searching the electronic databases and literature reviews and finding that no similar study had been undertaken in the region. This study compares numerous parameters between males and females with CF in the Azeri-Turkish population in Iran and surveys the role of a wide range of risk factors in explaining gender-related differences in the age of onset and diagnosis of CF. Ultimately, it could be effective in helping clinicians to manage this disease.

Materials and Methods

This was a cross sectional study (retrospective and prospective) conducted on 331 cases admitted to the Children's Educational and Treatment Hospital (the most governmental, specialized, and referral hospital in northwestern Iran) of the University of the Medical Sciences and Medical Genetic Laboratory, Tabriz, Iran between March 2001 and February 2015 using the census method, clinic visits, and by phone from the patients or their families. This study was performed on Azeri Turks who are one the largest ethnic groups in Iran19.

The diagnosis of CF was according to the typical clinical presentations based on the Guideline for Diagnosis of Cystic Fibrosis (Cystic Fibrosis Foundation Consensus Report) including chronic sinopulmonary disease, gastrointestinal and nutritional abnormalities, salt loss syndromes, and genital abnormalities which manifest as specific symptoms20 and abnormal sweat chloride values (>60 mEq/L) according to the method of Gibson and Cooke or the identification of mutations in CFTR gene known to cause CF21. Patients with incomplete records, incorrect recognition as having CF, and the kappa agreement rate lower than 85% were excluded with the reviewer's agreement.

Data had included sex, age, age at onset, age at diagnosis, ΔF508 mutation, outcome, cause of mortality, death age, duration of illness, and clinical presentations were extracted onto the extraction table. The age of onset referring to the age at which patients develops first experiences as symptoms of a disease or disorder with calculating the difference between the date of birth and onset of the first symptoms2022. The age of diagnosis referring to the age at which clinicians recognized disease for the first time first with calculating the difference between the date of birth and diagnosis of disease2023. The outcome variable was considered as living and deceased patients died because of chronic sinopulmonary disease, gastrointestinal and nutritional abnormalities, and salt loss syndromes.

Mean, standard deviation, median, interquartile range, frequency, percentage, mode, ratio, maximum, and minimum were calculated using SPSS version 18 (SPSS Inc., Chicago, IL, USA). Logistic regression analyses, chi-square test, independent-samples t test and Mann-Whitney U test were used for comparison between these parameters and gender. The normalizing of the data distribution was evaluated using the Kolmogorov-Smirnov test and the Shapiro-Wilk. An odds ratio (OR) with a 95% confidence interval, and a p≤0.05 indicated statistical significance. Ethical aspects were considered while approving the proposal by the Ethics Committee of the university (No. 5/4/1775) and obtaining permission from patients or their parents. Participation in this study was voluntary and subject information was kept secret even from the data analyzers.


Three hundred thirty-one cases were evaluated during the 14-year period. The demographic characteristics of the patients are represented in Table 1 and Figure 1. Most patients were males with a significant difference (p<0.001).

Demographic variables of CF patients

Figure 1

Age distribution is shown among cystic fibrosis (CF) patients alive in males and females.

Based on the Kolmogorov-Smirnov test and Shapiro-Wilk for age at onset and diagnosis (p<0.001), median was preferred to the mean because of non-normal distribution and associations between ages and genders were tested by a logistic regression model and the Mann-Whitney U test that have been represented in Table 1.

The median and minimum age at onset was approximately similar in both sexes, but the maximum age was higher in males than females. Association between age at onset and gender was not significant (p=0.3).

The median and maximum age at diagnosis was higher in males than females, but the minimum age was higher in females than males. Age at onset, age at diagnosis, age (living patients), age (deceased patients), and duration of illness are shown in Figure 2. Association between age at diagnosis and gender was significant with logistic regression analysis (OR, 0.94; 95% confidence interval, 0.89–0.1; p=0.05) and the Mann-Whitney U test (p=0.02). So, the probability of diagnosis increases by 6% in females than males of the same age (Table 1).

Figure 2

Gender difference for age at onset, age at diagnosis, age (living patients), age (deceased patients), and duration of illness in cystic fibrosis patients.

There were 86 deceased patients (25.9%) and 245 living patients (74.1%) at the time of the study. Of the 245 living CF patients, 202 (82.4%) were less than the age of 9 years, and 77 (89.5%) of the 85 deceased CF patients, had died younger than the age of 4 years.

Age distribution in males differed from females. Among females and males, patients alive were mostly under the age of 4 and 9 years and had died under the age of 9 and 15 years, respectively (Table 2, Figure 1).

Age distribution among cystic fibrosis patients

In the application of the Kolmogorov-Smirnov test and Shapiro-Wilk, age was assumed as non-normal distribution (p<0.001), consequently, median age for living patients was 4.76 years (0.4–50 years); and median and mode age at death were 0.48 years (7 days–30 years) and 2 months, respectively. Association between age for living patients and age at death with genders were not significant, respectively (p=0.2 and p=0.1). The cause of mortality was reviewed between sexes and this difference was not statistically significant. These variables and their associations with sexes are represented in Table 1.

Three hundred and thirty-one patients with CF, the median duration of illness was 2.46 years (7 days–30 years). Difference between two population medians (a non-parametric approach) was not significant (p=0.9); however, this value was somewhat higher in males than females.

The genetic characteristics of the two genders are represented in Table 1. There was no significant difference between gender and a positive genetic test with significant difference between gender and a positive genetic test for ΔF508. Females had a 49% greater likelihood of having the ΔF508 genotype than males.

Based on clinical presentations (at the time of onset, at the time of diagnosis, and over the lifespan), there was a noticeable difference in the age at diagnosis with respiratory symptoms over the lifespan and males presented their illness with delayed periods than females. This difference was not statistically significant at the rest materials with narrow disparities that have been represented (Table 3).

Comparison of age at onset and diagnosis based on clinical presentations between sexes


CF is often considered to be a problem that patients suffer from several serious complications of their disease throughout their lifetime. The aim of this study was to evaluate gender differences in a number of parameters in CF patients in the Azeri-Turkish population as follows:

The results of this study show that, sex ratio is approximately 2:1.5 (male:female) with a significant difference. This ratio was similar to the results of Jackson et al.22 who reported that amongst 601 patients, 328 were males and 273 were females. Corey et al.24 reported that, out of 499 patients from Boston and 538 patients from Toronto, percentage of male/female was 57/43 and 58/42, respectively with no significant differences24. This gender difference may be related to cultural matters4, an intrinsic ethnic difference14 or religious issues5.

In this study, there was a significant difference between gender and age at diagnosis; males had a considerably delayed diagnosis compared to females. Jackson et al.22 observed that males had a later median age at diagnosis (4.4 months) than females, although there was no statistical difference. In another study, the mean age of diagnosis was 18.6 months in males, while it was 22.6 months in females25. We observed variations in the results of different studies which may be because females reported problems more frequently and earlier due to being more sensitive or lower in body strength in our region. Previous studies have shown that females might be more sensitive or weaker than men, consequently presenting more problems12. In addition, malnutrition and a tendency towards respiratory infection in females1112627, hormonal changes15, a decline in physical activity and emotional functioning in female patients; and different emotions of mothers to female sex1312 could be additional factors causing an earlier presentation.

In current study, mean, median age, duration illness, age for living patients and the age of death were slightly predominant in males than females with no significant difference; in contrast an increasing risk for the ΔF508 mutation in females. Therefore females died younger or were diagnosed earlier than males. One study found that females die earlier than males particularly in the age group of 1–20 years26. When the mean age of current study was compared with results of other studies, it was found to be lower because of economic problems, unavailability of advanced diagnostic techniques and novel drugs; and the lack of coherent registry centers. Corey et al.24 reported the mean age 15.9±9.6 years and 15.2±8.3 years for CF patients in Boston and Toronto, respectively. Some studies have reported a longer median lifespan for males with no significant differences between sexes10. This difference may be due to a higher mortality rate, poor pulmonary function, a tendency towards respiratory infection, and malnutrition in females than in males1112131428. Olesen et al.15 over a study in the Scandinavian patients found a higher incidence of Pseudomonas infection among the female patients, resulting in the increasing of mortality rate, more days of hospitalization for females than males. Also, Sweezey and Ratjen26 and Davis29 were observed an increasing of mortality rate and a decrasing of the median survival age in CF females than males, significantly because of reduced pulmonary function, and decline of weight for height26. Some studies established that the homozygous ΔF508 mutation, which results in the display of symptoms at an earlier age, is more predominant in females than in males1030.

In addition to, males presented respiratory symptoms over the lifespan with a later median age at diagnosis than females. This difference was not significant for gastrointestinal and nutritional symptoms. Our findings were similar to those in a study had been conducted in the Republic of Ireland where males with gastrointestinal and respiratory symptoms were diagnosed 6.8 and 20.4 months later than females, respectively. In the U.K., female patients with gastrointestinal symptoms were diagnosed later, while in the United States, male patients with gastrointestinal symptoms were detected later22. Malnutrition110, decline in physical activity1, a decline in pulmonary function11012, and consequently the tendency to earlier colonization with Pseudomonas aeruginosa121531 as well as more reporting of respiratory symptoms in females were important factors. Therefore, respiratory symptoms appear earlier in females. However, reasons for this gender gap are still unclear and it is necessary to perform additional investigations in large populations.

There were several limitations in our study. The primary weakness of this study was a retrospective study with lesser precision although it does encourage future prospective research. The performing of investigation on specialist group reduces the ability to generalization of the study results. Data were limited to Children's Hospital and the Medical Genetic Laboratory in Tabriz between 2001 and 2015. It is possible that CF patients were not referred to these centers, or were diagnosed without registry.

The strength of this study was the adequate sample size considering the low incidence of CF in this region and its being conducted over a long period of time. Data was approved by two reviewers and were collected from educational, therapeutic and referral centers. This study was conducted at the Liver and Gastrointestinal Disease Research Centre of the University of Medical Sciences and in a population with a unique religion, ethnic origin, and culture, which could be a basis for the performance of comparative studies.

This study indicates associations between gender and ΔF508 mutation, age at diagnosis, and clinical presentation in our CF population. We found that this disease is more common in children younger than the age of nine years and more deaths were observed in those under the age of 4 years of age. Also, males were affected more than females. In contrast, ΔF508 mutation was detected in females than males. Age distribution differed between genders so that mortality and age distribution were observed at younger ages in females than in males. Disease was diagnosed later in males than in females, particularly with respiratory symptoms. The mortality rate, death age and duration of illness were somewhat further in males than males. The present study demonstrated differences between genders and the need for adequate care for females with this condition. With regard to the higher frequency of the disease and the delay in diagnosis, it is necessary to have a low threshold for requesting diagnostic tests in males. Finally, additional research should be directed toward identification and evaluation of other gender differences in CF.


Conflicts of Interest: No potential conflict of interest relevant to this article was reported.


1. Ernst MM, Johnson MC, Stark LJ. Developmental and psychosocial issues in cystic fibrosis. Child Adolesc Psychiatr Clin N Am 2010;19:263–283. 20478499.
2. Haworth CS, Selby PL, Horrocks AW, Mawer EB, Adams JE, Webb AK. A prospective study of change in bone mineral density over one year in adults with cystic fibrosis. Thorax 2002;57:719–723. 12149534.
3. Sorde R, Pahissa A, Rello J. Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis. Infect Drug Resist 2011;4:31–41. 21694907.
4. Salvatore D, Buzzetti R, Baldo E, Forneris MP, Lucidi V, Manunza D, et al. An overview of international literature from cystic fibrosis registries. Part 3. Disease incidence, genotype/phenotype correlation, microbiology, pregnancy, clinical complications, lung transplantation, and miscellanea. J Cyst Fibros 2011;10:71–85. 21257352.
5. Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros 2008;7:179–196. 18456578.
6. Luciani A, Villella VR, Esposito S, Gavina M, Russo I, Silano M, et al. Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on DeltaF508 cystic fibrosis transmembrane conductance regulator. Autophagy 2012;8:1657–1672. 22874563.
7. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997;145:794–803. 9143209.
8. Vahedi L, Jabarpoor-Bonyadi M, Ghojazadeh M, Hazrati H, Rafeey M. Association between outcomes and demographic factors in an Azeri Turkish population with cystic fibrosis: a cross-sectional study in Iran from 2001 through 2014. Iran Red Crescent Med J 2016;18:e29615. 27275400.
9. Harris H, Scotcher D, Hartley N, Wallace A, Craufurd D, Harris R. Cystic fibrosis carrier testing in early pregnancy by general practitioners. BMJ 1993;306:1580–1583. 8329921.
10. Verma N, Bush A, Buchdahl R. Is there still a gender gap in cystic fibrosis? Chest 2005;128:2824–2834. 16236961.
11. Abbott J, Morton AM, Musson H, Conway SP, Etherington C, Gee L, et al. Nutritional status, perceived body image and eating behaviours in adults with cystic fibrosis. Clin Nutr 2007;26:91–99. 17007968.
12. Groeneveld IF, Sosa ES, Perez M, Fiuza-Luces C, Gonzalez-Saiz L, Gallardo C, et al. Health-related quality of life of Spanish children with cystic fibrosis. Qual Life Res 2012;21:1837–1845. 22219170.
13. Schmidt A, Wenninger K, Niemann N, Wahn U, Staab D. Health-related quality of life in children with cystic fibrosis: validation of the German CFQ-R. Health Qual Life Outcomes 2009;7:97. 19954541.
14. Callaghan BD, Hoo AF, Dinwiddie R, Balfour-Lynn IM, Carr SB. Growth and lung function in Asian patients with cystic fibrosis. Arch Dis Child 2005;90:1029–1032. 16177157.
15. Olesen HV, Pressler T, Hjelte L, Mared L, Lindblad A, Knudsen PK, et al. Gender differences in the Scandinavian cystic fibrosis population. Pediatr Pulmonol 2010;45:959–965. 20672360.
16. Havermans T, Colpaert K, Vanharen L, Dupont LJ. Health related quality of life in cystic fibrosis: to work or not to work? J Cyst Fibros 2009;8:218–223. 19328745.
17. McCormick J, Mehta G, Olesen HV, Viviani L, Macek M Jr, Mehta A, et al. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet 2010;375:1007–1013. 20304245.
18. Arias Llorente RP, Bousono Garcia C, Diaz Martin JJ. Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros 2008;7:359–367. 18304896.
19. Bonyadi M, Omrani O, Rafeey M, Bilan N. Spectrum of CFTR gene mutations in Iranian Azeri Turkish patients with cystic fibrosis. Genet Test Mol Biomarkers 2011;15:89–92. 21198395.
20. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4–S14. 18639722.
21. De Boeck K, Bulteel V, Tiddens H, Wagner T, Fajac I, Conway S, et al. Guideline on the design and conduct of cystic fibrosis clinical trials: the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN). J Cyst Fibros 2011;10(Suppl 2):S67–S74. 21658644.
22. Jackson A, Foley L, Daly L, Fitzpatrick P, Harrington M, Zhou S, et al. Delayed cystic fibrosis presentation in children in the absence of newborn screening. Ir Med J 2010;103:113–116. 20486315.
23. Steinraths M, Vallance HD, Davidson AG. Delays in diagnosing cystic fibrosis: can we find ways to diagnose it earlier? Can Fam Physician 2008;54:877–883. 18556497.
24. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988;41:583–591. 3260274.
25. Farrell P, Joffe S, Foley L, Canny GJ, Mayne P, Rosenberg M. Diagnosis of cystic fibrosis in the Republic of Ireland: epidemiology and costs. Ir Med J 2007;100:557–560. 17955689.
26. Sweezey NB, Ratjen F. The cystic fibrosis gender gap: potential roles of estrogen. Pediatr Pulmonol 2014;49:309–317. 24339235.
27. Gee L, Abbott J, Hart A, Conway SP, Etherington C, Webb AK. Associations between clinical variables and quality of life in adults with cystic fibrosis. J Cyst Fibros 2005;4:59–66. 15752683.
28. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522–526. 17182652.
29. Davis PB. The gender gap in cystic fibrosis survival. J Gend Specif Med 1999;2:47–51.
30. Rodman DM, Polis JM, Heltshe SL, Sontag MK, Chacon C, Rodman RV, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005;171:621–626. 15591474.
31. Li Y, Zhang X, Wang C, Hu Y, Niu X, Pei D, et al. Characterization by phenotypic and genotypic methods of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis. Mol Med Rep 2015;11:494–498. 25323940.

Article information Continued

Figure 1

Age distribution is shown among cystic fibrosis (CF) patients alive in males and females.

Figure 2

Gender difference for age at onset, age at diagnosis, age (living patients), age (deceased patients), and duration of illness in cystic fibrosis patients.

Table 1

Demographic variables of CF patients

Variable Male Female p-value OR 95% CI
No. (%) 191 (57.7) 140 (42.3) <0.001 - -
Age at onset
 Mean 1.19 0.58 - - -
 Median (IQR) 0.16 (0.003–31) 0.16 (0.003–17) 0.12 0.93 0.84–1.02
Age at diagnosis
 Mean 2.58 1.32 - - -
 Median (IQR) 0.50 (0.003–50) 0.33 (0.2–27.29) 0.05 0.94 0.89–0.1
Deceased patients 51 (26.7) 35 (25) 0.4 1.09 0.66–1.80
Living patients 140 (73.3) 105 (75)
Age (living patients)
 Mean 7.16 6.18 0.06 0.94 0.88–1
 Median (IQR) 5.06 (0.42–50) 4.40 (0.62–31.2)
Age (deceased patients)
 Mean 2.43 1.22 0.2 0.92 0.81–1.05
 Median (IQR) 0.56 (7 days–30 years) 0.36 (0.02–11.6 years)
Cause of mortality C: 23 (45.1) C: 15 (42.9) 0.4 - -
G: 23 (45.1) G: 19 (54.3) - -
S: 5 (9.8) S: 1 (2.9) - -
Duration of illness
 Mean 3.62 3.31 0.9 0.48 0.96–1.07
 Median (IQR) 2.5 (7 days–18.4 years) 2.33 (7 days–30 years)
Positive for genetic testing, n (%) 112 (58.6) 85 (60.7) 0.3 0.88 0.67–1.164
Positive for ∆F508, n (%) 12 (6.3) 29 (20.7) <0.001 0.25 0.12–0.52
Infertility, n (%) 7 (3.7) 0 (0) 0.02 1.76 1.60–1.93

Values are presented as mean, median (IQR), or number (%). All age has been shown based on year and rest data based on number (%). Variables were considered for male/female. Age for CF patients alive and rest ages for alive and dead CF patients have been considered.

CF: cystic fibrosis; OR: odds ratio; CI: confidence interval; IQR: interquartile range; C: chronic sinopulmonary disease; G: gastrointestinal and nutritional abnormalities; S: salt loss syndromes.

Table 2

Age distribution among cystic fibrosis patients

Variable Male Female
Living patients Deceased patients Living patients Deceased patients
Age group, yr 140 (73.3) 51 (26.7) 105 (75) 34 (25)
 0–4 68 (47.9) 45 (88.2) 64 (60.4) 33 (92.4)
 5–9 46 (33.5) 3 (5.9) 23 (22) 2 (5.7)
 10–14 14 (10) 0 (0) 10 (10.4) 0 (0)
 Higher (≥15) 12 (8.6) 3 (5.9) 8 (6.6) 1 (2.9)

Values are presented as number (%).

For living cystic fibrosis patients, age at for the study and deceased patients, age at death has been considered.

Table 3

Comparison of age at onset and diagnosis based on clinical presentations between sexes

Clinical presentations at time onset Clinical presentations at time diagnosis Clinical presentations at lifespan
R p-value G p-value R p-value G p-value R p-value G p-value
Age at onset Male 0.17 0.8 0.17 0.5 0.17 0.9 0.17 0.6 0.17 0.1 0.17 0.9
Female 0.17 0.09 0.17 0.11 0.17 0.15
Age at diagnosis Male 0.5 0.1 0.44 0.2 0.5 0.3 0.44 0.1 0.58 0.001 0.48 0.2
Female 0.33 0.33 0.39 0.33 0.33 0.33

Data have been shown for R and G based on median years.

R: respiratory symptoms; G: gastrointestinal symptoms.